tetano
Editor, Senior Moderator
Leuk Lymphoma
. 2022 Oct 25;1-9.
doi: 10.1080/10428194.2022.2131414. Online ahead of print.
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome
David C Helfgott[SUP] 1 [/SUP], Sabrina Racine-Brzostek[SUP] 2 [/SUP], Kelsey J Short[SUP] 3 [/SUP], Zhen Zhao[SUP] 2 [/SUP], Paul Christos[SUP] 4 [/SUP], Itzel Nino[SUP] 3 [/SUP], Tina Niu[SUP] 3 [/SUP], Jorge Contreras[SUP] 3 [/SUP], Ellen K Ritchie[SUP] 3 [/SUP], Pinkal Desai[SUP] 3 [/SUP], Michael Samuel[SUP] 3 [/SUP], Gail J Roboz[SUP] 3 [/SUP]
Affiliations
Abstract
Immunocompromised patients are susceptible to complications from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The mRNA vaccines BNT162b2 and mRNA-1273 are effective in immunocompetent adults, but have diminished activity in immunocompromised patients. We measured anti-spike SARS-CoV-2 antibody (anti-S) response, avidity, and surrogate neutralizing antibody activity in COVID-19 vaccinated patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Anti-S was induced in 89% of AML and 88% of MDS patients, but median levels were significantly lower than in healthy controls. SARS-CoV-2 antibody avidity and neutralizing activity from AML patients were significantly lower than controls. Antibody avidity was significantly greater in patients after mRNA-1273 versus BNT162b2; there were trends toward higher anti-S levels and greater neutralizing antibody activity after mRNA-1273 vaccination. Patients with AML and MDS are likely to respond to COVID-19 mRNA vaccination, but differences in anti-S levels, avidity, and neutralizing antibody activity may affect clinical outcomes and require further study.
Keywords: COVID-19 vaccine immunogenicity; infectious complications of neoplasia; myeloid leukemias and dysplasias; the humoral immune response.
. 2022 Oct 25;1-9.
doi: 10.1080/10428194.2022.2131414. Online ahead of print.
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome
David C Helfgott[SUP] 1 [/SUP], Sabrina Racine-Brzostek[SUP] 2 [/SUP], Kelsey J Short[SUP] 3 [/SUP], Zhen Zhao[SUP] 2 [/SUP], Paul Christos[SUP] 4 [/SUP], Itzel Nino[SUP] 3 [/SUP], Tina Niu[SUP] 3 [/SUP], Jorge Contreras[SUP] 3 [/SUP], Ellen K Ritchie[SUP] 3 [/SUP], Pinkal Desai[SUP] 3 [/SUP], Michael Samuel[SUP] 3 [/SUP], Gail J Roboz[SUP] 3 [/SUP]
Affiliations
- PMID: 36282213
- DOI: 10.1080/10428194.2022.2131414
Abstract
Immunocompromised patients are susceptible to complications from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The mRNA vaccines BNT162b2 and mRNA-1273 are effective in immunocompetent adults, but have diminished activity in immunocompromised patients. We measured anti-spike SARS-CoV-2 antibody (anti-S) response, avidity, and surrogate neutralizing antibody activity in COVID-19 vaccinated patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Anti-S was induced in 89% of AML and 88% of MDS patients, but median levels were significantly lower than in healthy controls. SARS-CoV-2 antibody avidity and neutralizing activity from AML patients were significantly lower than controls. Antibody avidity was significantly greater in patients after mRNA-1273 versus BNT162b2; there were trends toward higher anti-S levels and greater neutralizing antibody activity after mRNA-1273 vaccination. Patients with AML and MDS are likely to respond to COVID-19 mRNA vaccination, but differences in anti-S levels, avidity, and neutralizing antibody activity may affect clinical outcomes and require further study.
Keywords: COVID-19 vaccine immunogenicity; infectious complications of neoplasia; myeloid leukemias and dysplasias; the humoral immune response.